US Edition
Mesoblast Limited (MESO) Stock Analysis: A Biotech with 127.85% Potential Upside
Summary by DirectorsTalk Interviews
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Mesoblast Limited (MESO) Stock Analysis: A Biotech with 127.85% Potential Upside
Mesoblast Limited (NASDAQ: MESO), an innovative player in the biotechnology sector, is capturing investor attention with a significant potential upside of 127.85%, according to recent analyst target prices. Headquartered in Melbourne, Australia, Mesoblast focuses on regenerative medicine, leveraging its proprietary mesenchymal lineage cells to tackle various systemic inflammatory and chronic conditions. #### Current Market Position Trading at $1…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
